News Headlines

  1. RoslinCT And BOOST Pharma Announce Strategic Manufacturing Agreement To Advance Cell Therapy For Infants With Osteogenesis Imperfecta 1/7/2026

    RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease.

  2. Codexis Expands Reach Of The ECO Synthesis® Manufacturing Platform Through A Signed Evaluation Agreement With Axolabs For Oligonucleotide Therapeutics 1/7/2026

    Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs, part of LGC Group, an oligonucleotide Contract Research Development and Manufacturing organization (CRDMO), today announced that they have entered into an agreement under which Axolabs will evaluate Codexis' ECO Synthesis Manufacturing Platform.

  3. Ascidian Therapeutics And Forge Biologics Announce Manufacturing Partnership To Advance RNA Editing Therapy For Stargardt Disease 1/7/2026

    Ascidian Therapeutics (“Ascidian”), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced a strategic partnership to advance the development and manufacturing of ACDN-01, Ascidian’s lead retinal program for the treatment of Stargardt disease.

  4. Cytora Therapeutics, Made Scientific, And Zeo ScientifiX Announce Partnership To Manufacture And Commercialize Cytora's Allogeneic Stem Cell Therapy In The United States 1/7/2026

    Cytora Therapeutics Ltd. (Cytora), a clinical-stage biotechnology company based in Israel developing allogeneic, stem cell therapies; Made Scientific, Inc. (Made Scientific), a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO); and Zeo ScientifiX, Inc. (Zeo), a Florida-based clinical-stage biopharmaceutical company specializing in research, clinical trials, manufacturing and the commercialization, and market access of biologics, today announced a comprehensive strategic partnership to advance and commercialize Cytora's novel allogeneic, off- the- shelf, human oral mucosal stem cell therapy in the United States.

  5. Convergent Therapeutics And Northstar Medical Radioisotopes Announce Expanded Partnership To Support Convergent's Late-Stage Alpha-Emitting Radioantibody Program 1/6/2026

    Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, and NorthStar Medical Radioisotopes (NorthStar), a leading radiopharmaceutical company, today announced an expanded agreement under which Convergent will support its drug development and clinical batch production with dedicated manufacturing suites on NorthStar’s Beloit, Wisconsin campus.

  6. Lineage Takes Delivery Of Gene-Edited Hypoimmune Cell Line Under Partnership With Factor Bioscience 1/6/2026

    Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, today announced the receipt of a novel, induced pluripotent stem cell (iPSC) line containing hypoimmunity edits, from Factor Bioscience Inc. (“Factor”).

  7. BostonGene And Astrazeneca Announce Strategic Collaboration To Advance Foundation Model-Driven Oncology Development 1/6/2026

    BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, to advance oncology drug development using BostonGene’s multimodal AI platform.

  8. Artis Biosolutions Announces Agreement To Acquire Syngoi Technologies To Deliver Next Generation Solutions For Synthetic DNA Technology 1/6/2026

    Artis BioSolutions (“Artis”), a San Diego-based advanced-therapies development and manufacturing company, today announced that it has entered into a definitive agreement to acquire Syngoi Technologies (“Syngoi”), a Spanish biotechnology company pioneering novel enzymatic approaches for manufacturing synthetic DNA technologies.

  9. PAI Pharma Acquires Nivagen Pharmaceuticals, Expanding Domestic Sterile Injectable Manufacturing And Expanding Ready-To-Use ('RTU') Product Offering In The Hospital Market 1/6/2026

    PAI Pharma ("PAI"), a portfolio company of Olympus Partners and a leading U.S. developer, manufacturer and marketer of oral liquid medicines, today announced the acquisition of Nivagen Pharmaceuticals, Inc. ("Nivagen"), a California-based pharmaceutical company with advanced aseptic manufacturing infrastructure and a robust pipeline of ready-to-use sterile injectables. 

  10. CDMO GBI Biomanufacturing Announces New President 1/6/2026

    GBI Biomanufacturing, a U.S.-based biopharmaceutical CDMO providing integrated development and cGMP manufacturing services for complex biologics, today announced that Jesse McCool, Ph.D. has been appointed President.